Dyne Therapeutics grabs $115M to ramp up muscle disease pipeline

DNA
Instead of using antibodies to deliver drugs to their target, Dyne is using them to deliver oligonucleotides, short pieces of DNA or RNA. (LionFive/Pixabay)

Dyne Therapeutics is back at the VC well—this time, it’s raising $115 million to bankroll a pipeline of treatments for muscle diseases including its lead programs for Duchenne muscular dystrophy and two other muscle-wasting diseases.

The top-up comes from Dyne’s backers Forbion, MPM Capital and Atlas Venture—which founded, seeded and incubated the company—as well as from newcomers Vida Ventures, Surveyor Capital, Wellington Management Company, Logos Capital and Franklin Templeton.

“We are excited to have such strong support from outstanding new and existing investors who share the Dyne team’s vision of building the world’s leading muscle disease company,” Dyne CEO Joshua Brumm said in a statement. “Importantly, this capital allows us to leverage our FORCE platform and advance our pipeline of modern oligonucleotide therapeutics aimed at transforming the lives of individuals living with serious muscle diseases.”

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

RELATED: Dyne starts life with $50M, big biopharma names for muscle disease work

The FORCE platform allows Dyne to conjugate antibodies to oligonucleotides—short DNA or RNA molecules—to treat serious muscle diseases. An antibody brings the payload to muscle cells, where the oligonucleotide binds with RNA that drives disease progression and degrades it.

RELATED: Muscle disorder biotech Avidity aims for the clinic with $100M IPO

The company has three preclinical-stage assets—in addition to its Duchenne program, it’s working on treatments for myotonic dystrophy Type 1 (DM1), a muscle wasting disorder caused by a mutation in the DMPK gene, and facioscapulohumeral muscular dystrophy (FSHD), which is caused by genetic changes in chromosome 4 and primarily affects muscles in the face, shoulder blades and upper arms. It is looking at cardiac and metabolic muscle diseases in its discovery-stage work.

Dyne isn’t the only player working on antibody-oligonucleotide conjugates. Avidity Biosciences is also using the approach to treat muscle diseases. The company raised $100 million in venture funding late last year and filed to raise $100 million in its IPO in May before closing its listing at $298 million. It expects its first program, in myotonic dystrophy Type 1, to enter the clinic in 2021.

Attaching drugs to antibodies to exploit their selective nature isn’t new—several companies are working on antibody-drug conjugates to deliver cell-killing drugs to cancer cells without harming healthy tissue. But Avidity and Dyne believe that using oligonucleotides could work even better.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.